Treatment of advanced non-small-cell lung cancer in the elderly

Lung Cancer

Volumn 66, Issue 3, 2009, Pages 282-286

  Gridelli, Cesare ^a   Maione, Paolo ^a   Rossi, Antonio ^a   Ferrara, Marianna Luciana ^b   Castaldo, Vincenzo ^a   Palazzolo, Giovanni ^c   Mazzeo, Nicole ^a  

^a S G MOSCATI HOSPITAL   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c Division of Radiation Oncology   (Italy)

Author keywords

Chemotherapy; Elderly patients; NSCLC; Targeted therapies

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PLACEBO; SORAFENIB; TAXANE DERIVATIVE; VANDETANIB;

ADVANCED CANCER; AGED; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; GERIATRIC PATIENT; HUMAN; HYPERTENSION; KIDNEY DISEASE; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MONOTHERAPY; NAUSEA; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROTOXICITY; NEUTROPENIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RASH; REVIEW; SURVIVAL TIME; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT; VOMITING;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CARCINOMA, NON-SMALL-CELL LUNG; CARDIOVASCULAR DISEASES; CISPLATIN; CLINICAL TRIALS AS TOPIC; COMORBIDITY; HUMANS; LUNG NEOPLASMS; QUINAZOLINES; RADIATION-SENSITIZING AGENTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70449102673     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.08.006     Document Type: Review

References (36)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
2. Ries L.A.G., Eisner M.P., and Kosary C.L. SEER Cancer Statistics Review 1975-2000 (2003), National Cancer Institute, Bethesda, MD. http://seer.cancer.gov/csr/1975_2000 [accessed on 30.06.2004]
3. Owonikoko T.K., Ragin C.C., Belani C.P., Oton A.B., Gooding W.E., Taioli E., et al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol 25 (2007) 5570-5577
4. Wingo P.A., Cardinez C.J., Landis S.H., Greenlee R.T., Ries L.A., Anderson R.N., et al. Long term trends in cancer mortality in the United States. Cancer 97 (2003) 3133-3275
5. Repetto L., Venturino A., Fratino L., Serraino D., Troisi G., Gianni W., et al. Geriatric oncology: a clinical approach to the older patient with cancer. Eur J Cancer 39 (2003) 870-880
6. Lewis J.H., Kilgore M.L., Goldman D.P., Trimble E.L., Kaplan R., Montello M.J., et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 21 (2003) 1383-1389
7. Jatoi A., Hillman S., Stella P., Green E., Adjei A., Nair S., et al. Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the north Central Cancer Treatment Group. J Clin Oncol 23 (2005) 9113-9119
8. Pfister D.G., Johnson D.H., Azzoli C.G., Sause W., Smith T.J., Baker Jr. S., et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22 (2004) 330-353
9. Gridelli C., Aapro M., Ardizzoni A., Calducci L., De Marinis F., Kelly K., et al. Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel. J Clin Oncol 23 (2005) 3125-3137
10. Elderly Lung Cancer Vinorelbine Italian Study (ELVIS) Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 91 (1999) 66-72
11. Gridelli C., Cigolari S., Gallo C., Manzione L., Ianniello G.P., Frontini L., et al. Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non-small-cell lung cancer elderly patients. Phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial. Lung Cancer 31 (2001) 277-284
12. Fidias P., Supko J.G., Martins R., Boral A., Carey R., Grossbard M., et al. A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer. Clin Cancer Res 7 (2001) 3942-3949
13. Kudoh S., Takeda K., Nakagawa K., Takada M., Katakami N., Matsui K., et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 24 (2006) 3657-3663
14. Gridelli C., Perrone F., Gallo C., Cigolari S., Rossi A., Piantedosi F., et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 95 (2003) 362-372
15. Ardizzoni A., Boni L., Tiseo M., Fossella F.V., Schiller J.H., Paesmans M., et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 99 (2007) 847-857
16. Langer C.J., Vangel M., and Schiller J. Age-specific subanalysis of ECOG 1594: fit elderly patients (70-80 yrs) with NSCLC do as well as younger pts (<70). Proc Am Soc Clin Oncol 22 (2003) 639
17. Kelly K., Giarritta S., and Hayes S. Should older patients receive combination chemotherapy for advanced stage non-small cell lung cancer? An analysis of Southwest Oncology trials 9509 and 9308. Proc Am Soc Clin Oncol 20 (2001) 329a
18. Belani C.P., and Fossella F.V. Phase III study (TAX 326) of docetaxel-cisplatin and docetaxel-carboplatin versus vinorelbine-cisplatin for the first-line treatment of advanced/metastatic non-small cell lung cancer: analyses in elderly patients. Lung Cancer 41 Suppl. 2 (2003) S18
19. Lilenbaum R.C., Herndon J.E., List M., Desch C., Watson D.M., Miller A.A., et al. Single-agent versus combination chemotherapy in advanced non-small cell lung cancer: a CALGB randomized trial of efficacy, quality of life, and cost-effectiveness. J Clin Oncol 23 (2005) 190-196
20. Hensing T.A., Peterman A.H., Schell M.J., Lee J.H., and Socinski M.A. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, stage IIIB or IV non small cell lung carcinoma treated with carboplatin and paclitaxel. Cancer 98 (2003) 779-788
21. Perrone F., Gallo C., and Gridelli C. Re: Cisplatin-based therapy for elderly patients with advanced non-small cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 94 (2002) 1029-1031
22. Feliu J., Martin G., Madronal C., Rodríguez-Jaráiz A., Castro J., Rodríguez A., et al. Combination of low-dose cisplatin and gemcitabine for treatment of elderly patients with advanced non small cell lung cancer. Cancer Chemother Pharmacol 52 (2003) 247-252
23. Ohe Y., Niho S., Kakinuma R., Kubota K., Ohmatsu H., Goto K., et al. A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small-cell lung cancer in elderly patients. Ann Oncol 15 (2004) 45-50
24. Gridelli C., Maione P., Illiano A., Piantedosi F.V., Favaretto A., Bearz A., et al. Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studies. J Clin Oncol 25 (2007) 4663-4669
25. Maestu I., Gómez-Aldaraví L., Torregrossa M.D., Camps C., Llorca C., Bosch C., et al. Gemcitabine and low dose carboplatin in the treatment of elderly patients with advanced non-small cell lung cancer. Lung Cancer 42 (2003) 345-354
26. Choi I.S., Kim B.S., Park S.R., Lee S.Y., Kim D.Y., Kim J.H., et al. Efficacy of modified regimen with attenuated doses of paclitaxel plus carboplatin combination chemotherapy in elderly and/or weak patients with advanced non small cell lung cancer. Lung Cancer 39 (2003) 99-101
27. Jackman D., Yeap B., Lindeman N., Fidias P., Rabin M.S., Temel J., et al. Phase II clinical trial of chemotherapy-naive patients > or =70 years of age treated with erlotinib for advanced non-small cell lung cancer. An analysis of quality of life and symptom response. J Clin Oncol 25 (2007) 760-766
28. Chen Y., Tsai C., Shih J., Perng R., and Whang-Peng J. Phase II randomized trial of erlotinib versus vinorelbine in chemotherapy-naive patients with advanced non-small-cell lung cancer aged ≥70 years in Taiwan. J Clin Oncol 27 18S (2009) 419s
29. Crinò L., Cappuzzo F., Zatloukal P., Reck M., Pesek M., Thompson J.C., et al. Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol 26 (2008) 4253-4260
30. Wheatley-Price P., Ding K., Seymour L., Clark G.M., and Shepherd F.A. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 26 (2008) 2350-2357
31. Gridelli C., Morabito A., Gebbia V., Mencoboni M., Carrozza F., Viganò M.G., et al. Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: the cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomised phase II trials. Lung Cancer (2009) April 18 [Epub ahead of print]
32. Herbst R.S., Sun Y., Korfee S., Germonprè P., Saijo N., Zhou C., et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZODIAC). J Clin Oncol 27 18S (2009) 807s
33. Ramalingam S.S., Dalhberg S.E., Langer C., Gray R., Belani C.P., Brahmer J.R., et al. Outcome for elderly advanced non-small cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of the ECOG 4599 study. J Clin Oncol 26 (2008) 60-65
34. Jager E., Wu Y., and Mezger J. Safety of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): M019390 (SAIL) study. Ann Oncol 19 Suppl. 8 (2008) viii93
35. Leighl N.B., Zatloukal P., Mezger J., Ramlau R., Archer V., Moore N., et al. Efficacy and safety of first-line bevacizumab and cisplatin/gemcitabine in elderly patients with advanced non-small cell lung cancer in the B017704 study (AVAiL). J Clin Oncol 27 18S (2009) 419s
36. Gridelli C. Treatment of advanced non small-cell lung cancer in the elderly: from best supportive care to the combination of platin-based chemotherapy and targeted therapies. J Clin Oncol 26 (2008) 13-15